Accutar Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AC0682 / Accutar Biotech
NCT05489679: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Terminated
1
6
RoW
AC682
Accutar Biotechnology Inc
Breast Cancer
09/23
09/23
NCT05080842: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Terminated
1
21
US
AC682
Accutar Biotechnology Inc
Breast Cancer
04/24
04/24
AC0176 / Accutar Biotech
NCT05241613: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Terminated
1
28
US
AC176
Accutar Biotechnology Inc
Metastatic Castration Resistant Prostate Cancer
03/24
03/24
NCT05673109: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Terminated
1
8
RoW
AC176
Accutar Biotechnology Inc
Metastatic Castration Resistant Prostate Cancer
10/23
10/23
AC699 / Accutar Biotech
AC699-001, NCT05654532: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Recruiting
1
60
US
AC699
Accutar Biotechnology Inc
Breast Cancer
07/24
12/24
AC676 / Accutar Biotech
NCT05780034: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Recruiting
1
60
US
AC676
Accutar Biotechnology Inc
Relapsed/Refractory B-cell Malignancies
07/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AC0682 / Accutar Biotech
NCT05489679: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Terminated
1
6
RoW
AC682
Accutar Biotechnology Inc
Breast Cancer
09/23
09/23
NCT05080842: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Terminated
1
21
US
AC682
Accutar Biotechnology Inc
Breast Cancer
04/24
04/24
AC0176 / Accutar Biotech
NCT05241613: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Terminated
1
28
US
AC176
Accutar Biotechnology Inc
Metastatic Castration Resistant Prostate Cancer
03/24
03/24
NCT05673109: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Terminated
1
8
RoW
AC176
Accutar Biotechnology Inc
Metastatic Castration Resistant Prostate Cancer
10/23
10/23
AC699 / Accutar Biotech
AC699-001, NCT05654532: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Recruiting
1
60
US
AC699
Accutar Biotechnology Inc
Breast Cancer
07/24
12/24
AC676 / Accutar Biotech
NCT05780034: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Recruiting
1
60
US
AC676
Accutar Biotechnology Inc
Relapsed/Refractory B-cell Malignancies
07/25
12/25

Download Options